In a retrospective study involving 235 patients with HCC undergoing anti-PD-1 monoclonal antibody treatment, reductions of more than 50% in AFP or PIVKA-II levels compared to baseline were associated with improved treatment response, OS, and PFS. This evidence concerns the gene AFP and hepatocellular carcinoma.